932359-76-7
Chemical Structure
FiVe1
- CAS No.: 932359-76-7
- Formula:C18H16Cl2N4
- Molecular Weight:359.25
IUPAC Name: 8-chloro-4-(4-(3-chlorophenyl)piperazin-1-yl)cinnoline
InChIKey: DZGXRHIQXADSDH-UHFFFAOYSA-N
SMILES: ClC1=CC(N2CCN(C3=C4C=CC=C(Cl)C4=NN=C3)CC2)=CC=C1
Biological Activity: FiVe1 is a vimentin (VIM) inhibitor. FiVe1 binds to the rod domain of VIM, causing metaphase VIM disassembly and hyperphosphorylation at Ser56, ultimately leading to mitotic catastrophe, multinucleation, and loss of stemness. FiVe1 has anticancer activity against soft tissue sarcomas. FiVe1 increases the sensitivity of ovarian cancer to Cisplatin (HY-17394). FiVe1 can be used for researches of mesenchymal cancers (including breast cancer and soft tissue sarcoma) and ovarian cancers[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
FiVe1 | 99.90% | FiVe1 is a vimentin (VIM) inhibitor. FiVe1 binds to the rod domain of VIM, causing metaphase VIM disassembly and hyperphosphorylation at Ser56, ultimately leading to mitotic catastrophe, multinucleation, and loss of stemness. FiVe1 has anticancer activity against soft tissue sarcomas. FiVe1 increases the sensitivity of ovarian cancer to Cisplatin (HY-17394). FiVe1 can be used for researches of mesenchymal cancers (including breast cancer and soft tissue sarcoma) and ovarian cancers. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
-
Similarity Score 0.80
HY-151424Vimentin-IN-1 -
Similarity Score 0.63
HY-Z8656Trazodone impurity 14 -
Similarity Score 0.58
HY-157392hMAO-A-IN-1 -
Similarity Score 0.57
HY-47599WAY-639418 -
Similarity Score 0.57
HY-147398Dopamine D4 receptor antagonist-1 -
Similarity Score 0.55
HY-W587508Trazodone impurity 7 -
Similarity Score 0.54
HY-W725833Trazodone impurity 7 dihydrochloride -
Similarity Score 0.54
HY-127179ML189 -
Similarity Score 0.53
HY-1095275-HT7 agonist 1 -
Explore the MedChemAI to find more analogs
References
- [1]. Michael J Bollong, et al. A vimentin binding small molecule leads to mitotic disruption in mesenchymal cancers. Proc Natl Acad Sci U S A. 2017 Nov 14;114(46):E9903-E9912. [Content Brief]
- [2]. Martínez-Peña F, et al. Synthesis and biological evaluation of novel FiVe1 derivatives as potent and selective agents for the treatment of mesenchymal cancers. Eur J Med Chem. 2022 Nov 15;242:114638. [Content Brief]
- [3]. Möltgen S, et al. Cisplatin Protein Binding Partners and Their Relevance for Platinum Drug Sensitivity. Cells. 2020 May 26;9(6):1322. [Content Brief]
